Skip to content

A comparative study of 12 hour versus 24 hour Modified Pritchard regimen in the management of Eclampsia and Preeclampsia

A comparative study of 12 hour versus 24 hour Modified Pritchard regimen in the management of Eclampsia and Preeclampsia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR201811515303983
Enrollment
730
Registered
2018-11-09
Start date
2018-11-15
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Circulatory System Pregnancy and Childbirth Preeclampsia and Eclampsia

Interventions

Modified Pritchard regimen

Sponsors

University of Michigan
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Antepartum, intrapartum, or postpartum eclampsia with a blood pressure of 140/90 mm Hg or higher after 20 weeks of pregnancy; proteinuria with a dipstick value of +1 or higher; and seizures not attributed to other causes among women with preeclampsia. 2. Severe preeclampsia with diastolic BP=110 mmHg on two occasions or systolic BP =160 mmHg plus at least 2 or more symptoms of imminent eclampsia 3. Patients who have documentation of having received loading dose of MgSO4 at referral clinics prior to referral will be eligible for randomization if they otherwise

Exclusion criteria

Exclusion criteria: 1. Eclampsia with complications (e.g. acute renal failure, HELLP syndrome [hemolysis, elevated liver enzymes, and low platelet count], or pulmonary edema) or 2. Patients with underlying renal disease 3. Contraindication to MgSO4 (e.g. drug hypersensitivity, myasthenia gravis, anuria, or oliguria), 4. Prior intake of any other anticonvulsant, and a history of epilepsy. 5. Refusal to give consent or unable to give consent (eg unconscious)

Design outcomes

Primary

MeasureTime frame
the occurrence of a fit any time after the completion of the third maintenance dose (MD3) after delivery or last fit, in the study arm or the 6th maintenance dose (MD6) after delivery or last fit in the control arm till 6th week postpartum).

Secondary

MeasureTime frame
The time interval (in hours) from initiation of treatment to the development of diuresis. (Diuresis will be defined as urine output > 400ml/4 hrs);Clinical evidence of toxicity (Absent tendon reflexes, RR <16cpm, coma);Development acute renal failure (urine output <25 mls/hr) after initiation of treatment;Clinically documented pulmonary oedema;Maternal death;Cerebrovascular accident (stroke);Perinatal death;2. 5th minute Apgar score;Respiratory distress (necessitating admission to NICU)

Countries

Ghana

Contacts

Public ContactTITUS BEYUO

Korle Bu Teaching Hospital

drbeyuo@gmail.com+233200284332

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026